Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the...

Pop Culture Group Co., Ltd Announces 10 for 1 Share Consolidation

Pop Culture Group Co., Ltd Announces 10 for 1 Share Consolidation

XIAMEN, China, July 9, 2026 /PRNewswire/ -- Pop Culture Group Co., Ltd (NASDAQ: CPOP) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares of par value US$0.01 each (the "Class A Ordinary...

Yatsen Group Announces Partnership with Sephora China, Cementing Position as a Science-Led Beauty Innovation Leader

Yatsen Group Announces Partnership with Sephora China, Cementing Position as a Science-Led Beauty Innovation Leader

GUANGZHOU, China, July 8, 2026 /PRNewswire/ -- Yatsen Group (NYSE: YSG), a world-class beauty innovation pioneer, recently announced a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership...

Bambu Lab Announces 48-Hour Charity Fundraiser to Support Venezuela Earthquake Relief

Bambu Lab Announces 48-Hour Charity Fundraiser to Support Venezuela Earthquake Relief

AUSTIN, Texas, July 8, 2026 /PRNewswire/ -- Building on the ongoing relief efforts of Bambu Lab LATAM, including a USD 50,000 contribution toward earthquake recovery in Venezuela, Bambu Lab today announced a further step: a 48-hour community...

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

ACTC No 1 (Lot Q) PTY LTD ANNOUNCES OFFERING OF AUD 1,200,000 SENIOR SECURED LOAN NOTE OFFER

ACTC No 1 (Lot Q) PTY LTD ANNOUNCES OFFERING OF AUD 1,200,000 SENIOR SECURED LOAN NOTE OFFER

MELBOURNE, Australia, July 7, 2026 /PRNewswire/ -- ACTC No 1 (Lot Q) Pty Ltd ACN 698 419 519 (the Issuer) is seeking to raise a total of AUD 1,200,000 in funds by the issue of loan notes, according to an announcement today by the underwriter Banner...

Xthings, Inc. Announces Quantum-Ready Security Initiative for Physical AI and Smart Spaces Ecosystem

Xthings, Inc. Announces Quantum-Ready Security Initiative for Physical AI and Smart Spaces Ecosystem

Company Advances Crypto-Agile Security Architecture to Support Long-Term Security, Physical AI, and Smart Spaces Innovation FREMONT, Calif., July 6, 2026 /PRNewswire/ -- Xthings, Inc. today announced a strategic initiative to develop a future-ready,...

High Great Innovation Announces Pricing for Three Formation Drone Platforms for Outdoor and Indoor Shows

High Great Innovation Announces Pricing for Three Formation Drone Platforms for Outdoor and Indoor Shows

The EMO Mini, EMO Plus and FYLO Mini expand the company's portfolio for large-scale outdoor formations, payload-enabled performances and close-proximity indoor experiences. NEW YORK, July 3, 2026 /PRNewswire/ -- High Great Innovation, a global...

Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies End-of-treatment data from ENHANCE did not...

POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services

POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services

GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 84
  • menu
    menu